We recently published 10 Small Stocks with Mighty Gains. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the top-performing stocks on Wednesday. Ironwood Pharmaceuticals soared by 23.32 percent ...
Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating ...
- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million - - Ended Q4 2025 with greater ...
Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent quarters. The company markets Linzess in the United States in collaboration with ...
On Nov. 10, Ironwood reported solid third-quarter results, beating estimates for both earnings and sales, backed by the high demand for its sole marketed product, Linzess (linaclotide). Concurrently, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results